StockGuide AI - assistant pour la recherche de marché

Les analystes de Carter Worth recommandent d'acheter des actions Incyte (INCY) alors qu'elles sortent d'une plage de sept mois

06/26/2026, 11:37 AM investing recommendation Analysts: analysts, Carter Worth biotech

Incyte, une entreprise biopharmaceutique, est prête pour une éventuelle rupture après avoir été stagnante pendant sept mois, les analystes suggérant une perspective haussière alors qu'elle vise à dépasser la barre des 125 $.

Les analystes d'UBS abaissent l'objectif de prix de Zealand Pharma (ZEAL) à 540 couronnes danoises en raison de préoccupations concernant la tolérabilité du survodutide

06/18/2026, 10:36 PM business rating_drop Analysts: analysts, UBS biotech

L'action de Zealand Pharma a subi des baisses significatives après des données décevantes sur son médicament contre la perte de poids, le survodutide, ce qui a conduit les analystes à réduire les prévisions de ventes et à se concentrer sur son autre médicament, le petrelintide, qui pourrait offrir de meilleures perspectives sur le marché de l'obésité.

Les analystes de JPMorgan mettent en avant la réouverture du marché des IPO biotech malgré l'activité continue des fusions et acquisitions dans la grande pharmacie

06/15/2026, 10:36 PM business review Analysts: analysts, JPMorgan biotech healthcare

Le secteur biotech connaît un regain d'activité sur le marché public, mais de nombreuses entreprises leaders pourraient préférer une acquisition par de plus grandes firmes pharmaceutiques plutôt que de poursuivre des introductions en bourse (IPO). Cette tendance reflète un climat d'investissement sélectif et un changement stratégique dans la manière dont les entreprises biotech abordent la croissance et le financement.

Biotech M&A Set for Strongest Year Since Pre-Pandemic as Deal Value Reaches $106 Billion in 2026

06/03/2026, 11:30 PM business review biotech healthcare

The biopharma sector is experiencing a significant surge in mergers and acquisitions, with 2026 poised to become the strongest year since before the pandemic, driven by patent expirations and a favorable market environment.

Abivax (ABVX) Shares Plunge Over 30% Following Update on Bowel Disease Drug Trial

06/02/2026, 12:31 AM stock_drop biotech

Abivax is strategically planning to raise funds following the release of crucial trial data, indicating its intent to remain independent amid ongoing takeover speculation, which has significantly influenced its stock performance.

Innovent Biologics (1801.HK) Shares Surge 10% Following $10.5 Billion Partnership with Pfizer

05/28/2026, 08:32 PM announcement biotech

Innovent Biologics has entered a strategic partnership with Pfizer, which is expected to enhance its oncology drug development capabilities.

Analysts BTIG initiate coverage of Absci Corporation (ABSI) with a buy rating and $9 price target, citing potential for ABS-201 in hair loss treatment

05/28/2026, 07:33 AM investing rating_growth Analysts: analysts, BTIG biotech

Absci Corporation's innovative hair loss treatment, ABS-201, has garnered a buy rating from BTIG, with a projected peak sales potential of $2.2 billion, indicating significant market opportunity in a largely underserved sector.

Analysts Goldman Sachs initiate coverage of Hemab Therapeutics (HEMA) with Buy rating and $36 target price, citing potential for unique bleeding disorder treatment

05/26/2026, 07:32 AM investing rating_growth Analysts: analysts, Goldman Sachs biotech

Hemab Therapeutics is positioned for significant growth following its IPO, driven by its development of unique treatments for rare bleeding disorders, as highlighted by Goldman Sachs' bullish outlook.

U.S. Promotes AI Technology in Asia Following Trump-Xi Meeting

05/22/2026, 05:34 AM business announcement ai biotech

The U.S. is intensifying efforts to promote American technology, particularly in artificial intelligence, in Asia amid competition with China, which is developing its own alternatives. This strategic push follows a recent meeting between Presidents Trump and Xi, highlighting the importance of U.S. tech in the region.

Biotech and Real Estate Sectors Show Mixed Performance Ahead of Key Oncology Meeting

05/21/2026, 04:32 PM investing review biotech real_estate

The upcoming meeting of the American Society of Clinical Oncology is poised to influence biotech stocks, which have shown significant gains over the past year despite recent fluctuations. Additionally, a substantial government investment in quantum computing has sparked notable stock increases in that sector.

Topic: biotech